ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

Two-Month Survival Benefit For Some NSCLC Patients

May 31, 2002

Funding Opportunities: NCI Schedules Meeting on RFA For Pathology Informatics

May 12, 2000

Funding Opportunities: NCI’s RAPID Program; RFA, Pas Avilable

May 14, 1999

Quality Of Care Varies Widely For Prostate Cancer, Study Says

August 29, 2008

FDA Approves Votrient For Soft Tissue Sarcomas

April 27, 2012

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009